Literature DB >> 23857971

Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.

Pier Paolo Piccaluga1, Fabio Fuligni, Antonio De Leo, Clara Bertuzzi, Maura Rossi, Francesco Bacci, Elena Sabattini, Claudio Agostinelli, Anna Gazzola, Maria Antonella Laginestra, Claudia Mannu, Maria Rosaria Sapienza, Sylvia Hartmann, Martin L Hansmann, Roberto Piva, Javeed Iqbal, John C Chan, Denis Weisenburger, Julie M Vose, Monica Bellei, Massimo Federico, Giorgio Inghirami, Pier Luigi Zinzani, Stefano A Pileri.   

Abstract

PURPOSE: The differential diagnosis among the commonest peripheral T-cell lymphomas (PTCLs; ie, PTCL not otherwise specified [NOS], angioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, with the morphologic and phenotypic features largely overlapping. We performed a phase III diagnostic accuracy study to test the ability of gene expression profiles (GEPs; index test) to identify PTCL subtype.
METHODS: We studied 244 PTCLs, including 158 PTCLs NOS, 63 AITLs, and 23 ALK-negative ALCLs. The GEP-based classification method was established on a support vector machine algorithm, and the reference standard was an expert pathologic diagnosis according to WHO classification.
RESULTS: First, we identified molecular signatures (molecular classifier [MC]) discriminating either AITL and ALK-negative ALCL from PTCL NOS in a training set. Of note, the MC was developed in formalin-fixed paraffin-embedded (FFPE) samples and validated in both FFPE and frozen tissues. Second, we found that the overall accuracy of the MC was remarkable: 98% to 77% for AITL and 98% to 93% for ALK-negative ALCL in test and validation sets of patient cases, respectively. Furthermore, we found that the MC significantly improved the prognostic stratification of patients with PTCL. Particularly, it enhanced the distinction of ALK-negative ALCL from PTCL NOS, especially from some CD30+ PTCL NOS with uncertain morphology. Finally, MC discriminated some T-follicular helper (Tfh) PTCL NOS from AITL, providing further evidence that a group of PTCLs NOS shares a Tfh derivation with but is distinct from AITL.
CONCLUSION: Our findings support the usage of an MC as additional tool in the diagnostic workup of nodal PTCL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23857971     DOI: 10.1200/JCO.2012.42.5611

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  46 in total

1.  A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.

Authors:  Ranjana H Advani; Stephen M Ansell; Mary J Lechowicz; Anne W Beaven; Fausto Loberiza; Kenneth R Carson; Andrew M Evens; Francine Foss; Steven Horwitz; Barbara Pro; Lauren C Pinter-Brown; Sonali M Smith; Andrei R Shustov; Kerry J Savage; Julie M Vose
Journal:  Br J Haematol       Date:  2015-12-02       Impact factor: 6.998

2.  A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Authors:  Oreofe Odejide; Oliver Weigert; Andrew A Lane; Dan Toscano; Matthew A Lunning; Nadja Kopp; Sunhee Kim; Diederik van Bodegom; Sudha Bolla; Jonathan H Schatz; Julie Teruya-Feldstein; Ephraim Hochberg; Abner Louissaint; David Dorfman; Kristen Stevenson; Scott J Rodig; Pier Paolo Piccaluga; Eric Jacobsen; Stefano A Pileri; Nancy L Harris; Simone Ferrero; Giorgio Inghirami; Steven M Horwitz; David M Weinstock
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

Review 3.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

4.  Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.

Authors:  Sanam Loghavi; Sa A Wang; L Jeffrey Medeiros; Jeffrey L Jorgensen; Xin Li; Zijun Y Xu-Monette; Roberto N Miranda; Ken H Young
Journal:  Leuk Lymphoma       Date:  2016-04-22

Review 5.  Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.

Authors:  Elaine S Jaffe; Paul M Barr; Sonali M Smith
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

6.  Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition.

Authors:  M R Sapienza; F Fuligni; C Agostinelli; C Tripodo; S Righi; M A Laginestra; A Pileri; M Mancini; M Rossi; F Ricci; A Gazzola; F Melle; C Mannu; F Ulbar; M Arpinati; M Paulli; T Maeda; D Gibellini; L Pagano; N Pimpinelli; M Santucci; L Cerroni; C M Croce; F Facchetti; P P Piccaluga; S A Pileri
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

7.  Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.

Authors:  G Visani; F Ferrara; F Di Raimondo; F Loscocco; G Sparaventi; S Paolini; F Fuligni; A Gazzola; M Rossi; M A Laginestra; M R Caraci; C Riccardi; M Rocchi; A Visani; S A Pileri; P P Piccaluga; A Isidori
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

8.  Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.

Authors:  S Spinner; G Crispatzu; J-H Yi; E Munkhbaatar; P Mayer; U Höckendorf; N Müller; Z Li; T Schader; H Bendz; S Hartmann; M Yabal; K Pechloff; M Heikenwalder; G L Kelly; A Strasser; C Peschel; M-L Hansmann; J Ruland; U Keller; S Newrzela; M Herling; P J Jost
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

Review 9.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.

Authors:  Alexandra Papoudou-Bai; Eleftheria Hatzimichael; Alexandra Barbouti; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2016-09-06       Impact factor: 3.984

Review 10.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.